Prucalopride

Prucalopride

Clinical data
Trade names	Resolor, Resotran
AHFS/Drugs.com	International Drug Names
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN
Pregnancy category	AU: B1 Not recommended
Routes of administration	Oral
ATC code	A06AX05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-Amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
CAS Number	179474-81-8 Y
PubChem CID	3052762
IUPHAR/BPS	243
ChemSpider	2314539
UNII	0A09IUW5TP
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H26ClN3O3
Molar mass	367.870 g/mol
3D model (JSmol)	Interactive image
SMILES COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
InChI InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23) Key:ZPMNHBXQOOVQJL-UHFFFAOYSA-N
(verify)

WikiDoc Resources for Prucalopride
Articles
Most recent articles on Prucalopride Most cited articles on Prucalopride Review articles on Prucalopride Articles on Prucalopride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Prucalopride Images of Prucalopride Photos of Prucalopride Podcasts & MP3s on Prucalopride Videos on Prucalopride
Evidence Based Medicine
Cochrane Collaboration on Prucalopride Bandolier on Prucalopride TRIP on Prucalopride
Clinical Trials
Ongoing Trials on Prucalopride at Clinical Trials.gov Trial results on Prucalopride Clinical Trials on Prucalopride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Prucalopride NICE Guidance on Prucalopride NHS PRODIGY Guidance FDA on Prucalopride CDC on Prucalopride
Books
Books on Prucalopride
News
Prucalopride in the news Be alerted to news on Prucalopride News trends on Prucalopride
Commentary
Blogs on Prucalopride
Definitions
Definitions of Prucalopride
Patient Resources / Community
Patient resources on Prucalopride Discussion groups on Prucalopride Patient Handouts on Prucalopride Directions to Hospitals Treating Prucalopride Risk calculators and risk factors for Prucalopride
Healthcare Provider Resources
Symptoms of Prucalopride Causes & Risk Factors for Prucalopride Diagnostic studies for Prucalopride Treatment of Prucalopride
Continuing Medical Education (CME)
CME Programs on Prucalopride
International
Prucalopride en Espanol Prucalopride en Francais
Business
Prucalopride in the Marketplace Patents on Prucalopride
Experimental / Informatics
List of terms related to Prucalopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Prucalopride (brand name Resolor, developed by Johnson & Johnson and licensed to Movetis) is a drug acting as a selective, high affinity 5-HT₄ receptor agonist which targets the impaired motility associated with chronic constipation, thus normalising bowel movements. Prucalopride was approved for use in Europe in 2009 and in Canada (named Resotran) on December 7, 2011 but it has not been approved by the Food and Drug Administration for use in the United States. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.

Mechanism of action

Prucalopride, a first in class dihydro-benzofuran-carboxamide, is a selective, high affinity serotonin (5-HT₄) receptor agonist with enterokinetic activities. Prucalopride alters colonic motility patterns via serotonin 5-HT₄ receptor stimulation: it stimulates colonic mass movements, which provide the main propulsive force for defecation.

The observed effects are exerted via highly selective action on 5-HT₄ receptors: prucalopride has >150-fold higher affinity for 5-HT₄ receptors than for other receptors. Prucalopride differs from other 5-HT₄ agonists such as tegaserod and cisapride, which at therapeutic concentrations also interact with other receptors (5-HT_1B/D and the cardiac human ether-a-go-go K⁺ or hERG channel respectively) and this may account for the adverse cardiovascular events that have resulted in the restricted availability of these drugs. Clinical trials evaluating the effect of prucalopride on QT interval and related adverse events have not demonstrated significant differences compared with placebo.

Pharmacokinetics

Prucalopride is rapidly absorbed (C_max attained 2–3 hours after single 2 mg oral dose) and is extensively distributed. Metabolism is not the major route of elimination. In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found. A large fraction of the active substance is excreted unchanged (about 60% of the administered dose in urine and at least 6% in faeces). Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. Plasma clearance averages 317 ml/min, terminal half-life is 24–30 hours, and steady-state is reached within 3–4 days. On once daily treatment with 2 mg prucalopride, steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively.

In vitro data indicate that prucalopride has a low interaction potential, and therapeutic concentrations of prucalopride are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products.

Efficacy

The primary measure of efficacy in the clinical trials is three or more spontaneous complete bowel movements per week; a secondary measure is an increase of at least one complete spontaneous bowel movement per week. Further measures are improvements in PAC-QOL (a quality of life measure) and PAC-SYM (a range of stool, abdominal, and rectal symptoms associated with chronic constipation). Infrequent bowel movements, bloating, straining, abdominal pain, and defecation urge with inability to evacuate can be severe symptoms, significantly affecting quality of life.

In three large clinical trials, 12 weeks of treatment with prucalopride 2 and 4 mg/day resulted in a significantly higher proportion of patients reaching the primary efficacy endpoint of an average of ≥3 spontaneous complete bowel movements than with placebo. There was also significantly improved bowel habit and associated symptoms, patient satisfaction with bowel habit and treatment, and HR-QOL in patients with severe chronic constipation, including those who did not experience adequate relief with prior therapies (>80% of the trial participants). The improvement in patient satisfaction with bowel habit and treatment was maintained during treatment for up to 24 months; prucalopride therapy was generally well tolerated.

Side effects

Prucalopride has been given orally to ~2700 patients with chronic constipation in controlled clinical trials. The most frequently reported side effects are headache and gastrointestinal symptoms (abdominal pain, nausea or diarrhoea). Such reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment.

Prescribing information

In the EEA, prucalopride is approved for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. The recommended dosage in adults is 2 mg administered orally once daily; exceeding this dosage is not expected to increase efficacy. The recommended starting dose in elderly patients (>65 years) is 1 mg once daily; thereafter the dosage can be increased to 2 mg once daily, if needed.

Contraindications

Prucalopride is contraindicated where there is hypersensitivity to the active substance or to any of the excipients, renal impairment requiring dialysis, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon/megarectum.

External links

• Resolor (prucalopride)- Movetis